Moroccan Pharma Group Laprophan Prices Casablanca IPO at MAD 341 to Fund Polymedic Purchase
Laprophan set the final price for its Casablanca Stock Exchange debut at MAD 341 a share on November 19, closing a subscription window meant to help fund its purchase of the laboratory Polymedic.
The Moroccan pharmaceutical group is raising up to MAD 2.22bn (about $223 million), Radarr Africa reported from Casablanca. Subscriptions ran from November 9 to November 17, closing at 3:30 pm on the final day. Under the issue timetable, Thursday is the deadline for centralising orders, allocation of shares falls on November 23, and the first day of trading is November 25.
The listing matters beyond the offer price. It converts a Casablanca laboratory founded in 1949 into a listed company using public money to buy a rival — and it hands Morocco’s pharmaceutical sector one of its most visible consolidation stories.
Through this listing, Laprophan is tapping public markets to tighten its grip on Morocco’s pharmaceutical industry, bringing a long-established rival into the fold while extending its footprint across borders. The deal turns an acquisition strategy into a listed growth story on the Casablanca exchange.
Chief executive Farid Bennis described the laboratory as a “national asset” because of its trailblazing past, in the original French “bien national”, Radarr Africa reported, citing his original French phrasing.
The words carry weight in a market where a 1964-founded competitor with about 280 employees and more than 200 products is about to fold into a 1949-founded incumbent with about 1,450 staff, more than 1,300 marketing authorisations, four production sites in Morocco and Switzerland, and sales in 52 countries.
How the MAD 341 offer splits up
The offer combines new shares and the sale of existing ones. Radarr Africa reported that the offer consists of 4,105,500 newly issued shares valued at up to MAD 1.4bn alongside 2,412,200 existing shares valued at up to MAD 822.56m. Share capital stands at MAD 132.1m, and the share count rises from 13.2 million to 17.3 million. In total, the offer represents about 37.6 per cent of capital, of which 23.7 per cent is newly created shares.
Three tranches divide the allocation. The largest, reserved for orders of at least 8,800 shares — a minimum order worth MAD 3,000,800 — takes 72.4 per cent. A second tranche with no minimum takes 22.5 per cent, and a third, reserved for employees and executives at a discounted MAD 273 per share, takes 5.1 per cent. Non-fund investors are capped at 10 per cent of the shares offered, or 651,770 shares.
The numbers behind techno listing
The financial record explains why the company could price at MAD 341. Consolidated revenue rose from MAD 1.503bn in 2023 to MAD 1.82bn in 2025, an average of about 10 per cent a year, Radarr Africa reported. In 2025, operating income reached MAD 264.6m, a 45.3 per cent increase, while net income climbed 33.9 per cent to MAD 109.4m — equivalent to 6.0 per cent of revenue, against 4.0 per cent in 2023. First-half 2026 revenue was MAD 1.354bn, up 11.4 per cent.
| Measure | Figure | Period / change |
|---|---|---|
| Consolidated revenue | MAD 1.503bn | 2023 |
| Consolidated revenue | MAD 1.82bn | 2025 (about 10% a year on average) |
| Operating income | MAD 264.6m | 2025, up 45.3% |
| Net income | MAD 109.4m | 2025, up 33.9% (6.0% of revenue vs 4.0% in 2023) |
Why Polymedic sits at the centre
In October 2026, Laprophan signed a deal for 100 per cent of Corporate Investment Holding, Polymedic’s parent company, pending approval from Morocco’s Competition Council. Polymedic’s 2025 revenue was MAD 405m and it is expected to reach about MAD 455m in 2026.
The purchase is not an isolated move. According to Radarr Africa, Laprophan acquired AIF Pharma in March 2024, took a 75 per cent holding in Botanic Pharma in September 2024, and secured a majority position in the Swiss firm Rivopharm in 2026. The Polymedic deal extends that run — and the IPO, with its MAD 1.4bn capital increase, gives it funding that a private balance sheet alone might not have carried.
Who is behind the deal
Mediterrania Capital Partners, an investor consortium, entered Laprophan’s capital in 2023, Radarr Africa reported. On the advisory side, CFG Finance serves as financial adviser and global coordinator, CFG Marches acts as lead manager, and Attijari Intermediation fills the co-lead manager role. Morocco’s capital markets authority, the AMMC, approved the prospectus on October 28, 2026.
Via an initial public offering on the Casablanca Stock Exchange, Laprophan is seeking up to 2,220,000,000 MAD (≈$223 million), with shares priced at 341 MAD each.
What happens between now and November 25
The timetable leaves little slack. Per the issue timetable, orders are centralised on Thursday, allocation of shares takes place on November 23, and the first trading day is November 25. The expected market value is about MAD 5.9bn.
For investors and advisers tracking the transaction — from corporate lawyers monitoring the Competition Council’s review of the Polymedic purchase to brokerage firms handling retail orders under the 651,770-share cap — the next checkpoint is the Competition Council’s approval, which the deal still awaits.
That clearance is the open question. The Polymedic acquisition, the stated purpose for part of the proceeds, cannot complete until the Competition Council approves the takeover of Corporate Investment Holding, and neither source reports a date for that decision.
Polymedic, founded in Morocco in 2001, is a generics manufacturer with a portfolio of more than 200 registered products across 12 therapeutic areas. In November 2019, Foursan Capital Partners II and NBK Capital Partners together acquired 98 per cent of its shares, growing its workforce by 67 per cent to 250 employees before selling the stake in August 2025 to a consortium of Moroccan businesspersons with pharmaceuticals and healthcare expertise.
Trading begins on November 25, according to the issue timetable.